Abstract | OBJECTIVES: Following the first hearttransplantin Ireland in 1985, there have been almost 700 deceased donor heart and lung transplants carried out in Ireland at a single institution. In this retrospective study, our aim was to assess the incidence and management of urological malignancies arising in this national cohort. MATERIALS AND METHODS: Our retrospective analysis included all heart and lung transplant recipients identified as having a urological malignancy. Primary outcome variables included incidence, management, and clinical outcomes following cancer diagnosis. RESULTS: CONCLUSIONS: Urological malignancies are not common in heart and lung transplant recipients; however, standard management options can be safely used, including radical surgery. Prospective monitoring of these patients and potential considerations for screening should be maintained.
|
Authors | Robert A Keenan, Usman Haroon, Paul Ryan, Bronagh Harrington, Andrew Jones, Mohammed Aboelmagd, Stephen Connolly, Kiaran J O'Mally, David Galvin, Nicholas Hegarty |
Journal | Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
(Exp Clin Transplant)
Vol. 19
Issue 10
Pg. 1069-1075
(10 2021)
ISSN: 2146-8427 [Electronic] Turkey |
PMID | 34641776
(Publication Type: Journal Article)
|
Topics |
- Carcinoma, Transitional Cell
(etiology)
- Cohort Studies
- Female
- Heart Transplantation
(adverse effects)
- Humans
- Incidence
- Kidney Transplantation
(adverse effects)
- Lung
- Male
- Prospective Studies
- Retrospective Studies
- Risk Factors
- Tissue Donors
- Transplant Recipients
- Treatment Outcome
- Urinary Bladder Neoplasms
(etiology)
- Urologic Neoplasms
(diagnosis, epidemiology, surgery)
|